X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AJANTA PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AJANTA PHARMA DR. REDDYS LAB/
AJANTA PHARMA
 
P/E (TTM) x 28.0 21.4 131.0% View Chart
P/BV x 3.0 5.0 59.8% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 DR. REDDYS LAB   AJANTA PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
AJANTA PHARMA
Mar-18
DR. REDDYS LAB/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7881,818 153.4%   
Low Rs1,9021,106 171.9%   
Sales per share (Unadj.) Rs860.8239.5 359.4%  
Earnings per share (Unadj.) Rs57.152.8 108.1%  
Cash flow per share (Unadj.) Rs122.059.5 205.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.7230.0 329.5%  
Shares outstanding (eoy) m165.9188.77 186.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.76.1 44.6%   
Avg P/E ratio x41.127.7 148.4%  
P/CF ratio (eoy) x19.224.6 78.2%  
Price / Book Value ratio x3.16.4 48.7%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,034129,782 299.8%   
No. of employees `00023.56.8 346.2%   
Total wages/salary Rs m32,1493,765 854.0%   
Avg. sales/employee Rs Th6,070.83,128.4 194.1%   
Avg. wages/employee Rs Th1,366.6554.0 246.7%   
Avg. net profit/employee Rs Th402.5689.7 58.4%   
INCOME DATA
Net Sales Rs m142,81021,258 671.8%  
Other income Rs m1,552242 642.4%   
Total revenues Rs m144,36221,499 671.5%   
Gross profit Rs m23,5126,584 357.1%  
Depreciation Rs m10,772596 1,807.7%   
Interest Rs m7884 19,219.5%   
Profit before tax Rs m13,5046,226 216.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3801,539 284.6%   
Profit after tax Rs m9,4684,686 202.0%  
Gross profit margin %16.531.0 53.2%  
Effective tax rate %32.424.7 131.2%   
Net profit margin %6.622.0 30.1%  
BALANCE SHEET DATA
Current assets Rs m104,98412,236 858.0%   
Current liabilities Rs m68,9383,461 1,992.1%   
Net working cap to sales %25.241.3 61.1%  
Current ratio x1.53.5 43.1%  
Inventory Days Days7460 123.5%  
Debtors Days Days10484 122.6%  
Net fixed assets Rs m104,38511,140 937.0%   
Share capital Rs m830177 469.2%   
"Free" reserves Rs m124,88620,237 617.1%   
Net worth Rs m125,71620,414 615.8%   
Long term debt Rs m25,08910 248,405.9%   
Total assets Rs m225,44324,486 920.7%  
Interest coverage x18.11,519.4 1.2%   
Debt to equity ratio x0.20 40,336.0%  
Sales to assets ratio x0.60.9 73.0%   
Return on assets %4.519.2 23.7%  
Return on equity %7.523.0 32.8%  
Return on capital %9.730.5 31.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62311,667 622.4%   
Fx outflow Rs m18,9161,616 1,170.9%   
Net fx Rs m53,70710,052 534.3%   
CASH FLOW
From Operations Rs m18,0302,854 631.7%  
From Investments Rs m-14,883-2,604 571.5%  
From Financial Activity Rs m-4,440-2 222,000.0%  
Net Cashflow Rs m-1,236248 -498.2%  

Share Holding

Indian Promoters % 25.5 73.8 34.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 1.6 348.4%  
FIIs % 35.3 7.6 464.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.0 90.0%  
Shareholders   75,885 20,968 361.9%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 14, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - TORRENT PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS